Researchers at Baylor College of Medicine and collaborating institutions are developing a strategy to predict the response of triple negative breast cancer (TNBC) to chemotherapy, which would be a valuable tool for physicians deciding on the treatment with better probability of success on an individual basis.
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 – Biotech Investments
Sartorius Stedim Biotech SA / Key word(s): 9 Month figures Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 17-Oct-2024 /